CriticalSSRI (selective serotonin reuptake inhibitor)×Prokinetic, peripheral dopamine D2 receptor antagonist
Updated · Methodology
Mechanism
In healthy volunteers, citalopram increased the Fridericia-corrected QT interval from baseline by 7.5 ms at 20 mg a day and by 16.7 ms at 60 mg a day (citalopram summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Post-marketing reports for citalopram describe QT prolongation and ventricular arrhythmias, including torsade de pointes (AEMPS). Domperidone is associated with QT prolongation. Epidemiological studies also link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day, and with QT-prolonging drugs (domperidone SmPC, AEMPS). The two drugs have not been studied together, but the citalopram SmPC does not rule out an additive effect on QT. The domperidone SmPC lists citalopram among the contraindicated antidepressants because pharmacodynamic or pharmacokinetic interactions raise the risk of QT prolongation (citalopram and domperidone SmPCs, AEMPS). In the liver, CYP3A4 is the main enzyme that metabolises domperidone, and citalopram is only a negligible inhibitor of this enzyme (domperidone and citalopram SmPCs, AEMPS). The documents give no data on either drug changing the level of the other.
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes dizziness, palpitations or fainting (citalopram label, US Food and Drug Administration, FDA). After citalopram was marketed, QT prolongation and ventricular arrhythmias, including torsade de pointes, were reported mainly in women and in people with low potassium, pre-existing QT prolongation or heart disease (citalopram summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With domperidone, QT prolongation and torsade de pointes have been reported very rarely, and these reports included people with other risk factors, electrolyte disturbances or concomitant medicines (domperidone SmPC, AEMPS). The risk of arrhythmia is higher with low or high potassium, low magnesium or a slow heart rate (domperidone SmPC, AEMPS).
Management
The combination is contraindicated. The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with QT-prolonging drugs and names citalopram among these antidepressants (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish citalopram SmPC also contraindicates citalopram with drugs that prolong the QT interval, and the US label says to avoid such combinations. According to its own SmPC, domperidone is associated with QT prolongation (citalopram SmPC, AEMPS, and citalopram label, US Food and Drug Administration, FDA; domperidone SmPC, AEMPS). Domperidone is also contraindicated in known QT prolongation, significant electrolyte disturbances and heart disease such as congestive heart failure (AEMPS), and citalopram in people with a history of QT prolongation or congenital long QT syndrome (citalopram SmPC, AEMPS). Use domperidone at the lowest effective dose, no more than 30 mg a day and usually for no longer than one week (domperidone SmPC, AEMPS). The recommended maximum dose of citalopram in people over 65 is 20 mg a day (citalopram SmPC, AEMPS). Correct low potassium and magnesium before starting citalopram (AEMPS), and stop citalopram if the heart-rate-corrected QT interval (QTc) stays above 500 ms (citalopram label, FDA). If domperidone and citalopram have nevertheless been taken together and signs of arrhythmia appear, stop domperidone (domperidone SmPC, AEMPS), stop citalopram as well and record an electrocardiogram (citalopram SmPC, AEMPS). No document says how long to wait between stopping one drug and starting the other. The half-life is about 33 hours for citalopram and 7–9 hours for domperidone (citalopram and domperidone SmPCs, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Citalopram, Seropram 30 mg (nº registro 63564) (2024)– AEMPS, CIMA, nº registro 63564 (Seropram 30 mg comprimidos recubiertos con película, Lundbeck), revisión 01/2024, secciones 4.2, 4.3, 4.4, 4.5 y 5.1
- FDA: Celexa (citalopram) – Prescribing Information (2023)– FDA, DailyMed SPL, Allergan, setid 4259d9b1-de34-43a4-85a8-41dd214e9177, version 40, revised 10/2023, sections 4, 5.2, 5.3, 5.4, 7, 12.3 and 17
- AEMPS: Ficha técnica: Domperidona (nº registro 55411), sección 4.3 (2025)– AEMPS, CIMA, nº registro 55411 (Motilium 1 mg/ml suspensión oral, Esteve), revisión 09/2025, secciones 4.2, 4.3, 4.4 y 4.5